These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24201549)

  • 41. Intensity-modulated salvage radiotherapy with simultaneous integrated boost for local recurrence of prostate carcinoma: a pilot study on the place of PET-choline for guiding target volume delineation.
    Wahart A; Guy JB; Vallard A; Geissler B; Ben Mrad M; Falk AT; Prevot N; de Laroche G; Rancoule C; Chargari C; Magné N
    Br J Radiol; 2016; 89(1058):20150579. PubMed ID: 26648528
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.
    Fodor A; Berardi G; Fiorino C; Picchio M; Busnardo E; Kirienko M; Incerti E; Dell'Oca I; Cozzarini C; Mangili P; Pasetti M; Calandrino R; Gianolli L; Di Muzio NG
    BJU Int; 2017 Mar; 119(3):406-413. PubMed ID: 27104782
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 11C-choline PET/CT and PSA kinetics.
    Castellucci P; Picchio M
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40 Suppl 1():S36-40. PubMed ID: 23579864
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 11C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer.
    Esch LH; Fahlbusch M; Albers P; Hautzel H; Müller-Mattheis V
    BJU Int; 2017 Sep; 120(3):337-342. PubMed ID: 27860163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer.
    Dost RJ; Glaudemans AW; Breeuwsma AJ; de Jong IJ
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40 Suppl 1():S41-7. PubMed ID: 23564037
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of [(11)C]choline Positron Emission Tomography With T2- and Diffusion-Weighted Magnetic Resonance Imaging for Delineating Malignant Intraprostatic Lesions.
    Chang JH; Lim Joon D; Davis ID; Lee ST; Hiew CY; Esler S; Gong SJ; Wada M; Clouston D; O'Sullivan R; Goh YP; Bolton D; Scott AM; Khoo V
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):438-45. PubMed ID: 25864171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. (11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients.
    Picchio M; Berardi G; Fodor A; Busnardo E; Crivellaro C; Giovacchini G; Fiorino C; Kirienko M; Incerti E; Messa C; Gianolli L; Di Muzio N
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1270-9. PubMed ID: 24599378
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Coradeschi E; Bettinardi V; Gianolli L; Scattoni V; Cozzarini C; Di Muzio N; Rigatti P; Fazio F; Messa C
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):301-9. PubMed ID: 19756592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study.
    Ceci F; Schiavina R; Castellucci P; Brunocilla E; Fuccio C; Colletti PM; Ferretti A; Chondrogiannis S; Rubello D; Romagnoli D; Malizia C; Martorana G; Fanti S
    Clin Nucl Med; 2013 Jul; 38(7):e279-82. PubMed ID: 23698461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.
    Ceci F; Castellucci P; Graziani T; Schiavina R; Chondrogiannis S; Bonfiglioli R; Costa S; Virgolini IJ; Rubello D; Fanti S; Colletti PM
    Clin Nucl Med; 2015 May; 40(5):e265-70. PubMed ID: 25783519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy.
    Picchio M; Spinapolice EG; Fallanca F; Crivellaro C; Giovacchini G; Gianolli L; Messa C
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):13-26. PubMed ID: 21932120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment.
    Detti B; Scoccianti S; Franceschini D; Cipressi S; Cassani S; Villari D; Gacci M; Pupi A; Vaggelli L; Saieva C; Pertici M; Livi L; Ceroti M; Nicita G; Carini M; Biti G
    J Cancer Res Clin Oncol; 2013 Mar; 139(3):521-8. PubMed ID: 23183655
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy.
    Reske SN; Blumstein NM; Glatting G
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):9-17. PubMed ID: 17828534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy.
    Rinnab L; Simon J; Hautmann RE; Cronauer MV; Hohl K; Buck AK; Reske SN; Mottaghy FM
    World J Urol; 2009 Oct; 27(5):619-25. PubMed ID: 19234708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of ¹¹C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation.
    Bertagna F; Abuhilal M; Bosio G; Simeone C; Rossini P; Pizzocaro C; Orlando E; Finamanti M; Biasiotto G; Rodella C; Cosciani Cunico S; Giubbini R
    Jpn J Radiol; 2011 Jul; 29(6):394-404. PubMed ID: 21786095
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.
    Schilling D; Schlemmer HP; Wagner PH; Böttcher P; Merseburger AS; Aschoff P; Bares R; Pfannenberg C; Ganswindt U; Corvin S; Stenzl A
    BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Restaging prostate cancer patients with biochemical failure with PET/CT and radiolabeled choline.
    Giovacchini G; Breeuwsma AJ
    Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):354-66. PubMed ID: 23013665
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.
    Krause BJ; Souvatzoglou M; Herrmann K; Weber AW; Schuster T; Buck AK; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler SI; Senekowitsch-Schmidtke R; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1861-8. PubMed ID: 20512572
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
    Calabria F; Chiaravalloti A; Tavolozza M; Ragano-Caracciolo C; Schillaci O
    Nucl Med Commun; 2013 Aug; 34(8):733-40. PubMed ID: 23680652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [ROLE OF KINETIC PERFORMANCE OF PSA IN SELECTION OF THE PATIENTS FOR CONDUCTION OF 11C-CHOLINE PET/CT AIMED TO REVEAL LOCAL RECURRENCES OF PROSTATE CANCER].
    Rybalov MA; De Iong IY; Breusma AI; Al'-Shukri SKh; Borovets SY
    Vestn Khir Im I I Grek; 2015; 174(6):25-8. PubMed ID: 27066654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.